Menu Search
Equities

Cardiff Oncology Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
XE7C:MUN

Cardiff Oncology Inc

Actions
  • Price (EUR)1.32
  • Today's Change-0.01 / -0.75%
  • Shares traded100.00
  • 1 Year change-67.43%
  • Beta1.3626
Data delayed at least 15 minutes, as of Feb 18 2026 07:01 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Cardiff Oncology Inc had net income fall 9.63% from a loss of 41.44m to a larger loss of 45.43m despite a 39.96% increase in revenues from 488.00k to 683.00k.
Gross margin--
Net profit margin-10,064.27%
Operating margin-10,719.56%
Return on assets-79.61%
Return on equity-102.76%
Return on investment-101.41%
More ▼

Cash flow in USDView more

In 2024, Cardiff Oncology Inc increased its cash reserves by 137.68%, or 29.82m. Cash Flow from Financing totalled 53.78m or 7,874.08% of revenues. In addition the company used 37.69m for operations while cash from investing totalled 13.73m.
Cash flow per share-0.7881
Price/Cash flow per share--
Book value per share0.7272
Tangible book value per share0.7272
More ▼

Balance sheet in USDView more

Cardiff Oncology Inc has a strong Balance Sheet and has consistently grown its cash reserves over the last four years to total 51.47m.
Current ratio4.20
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.